Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
Background Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (...
Gespeichert in:
| Veröffentlicht in: | Targeted oncology 2020-02, Vol.15 (1), p.93-100 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100 |
|---|---|
| container_issue | 1 |
| container_start_page | 93 |
| container_title | Targeted oncology |
| container_volume | 15 |
| creator | Huang, Di Zhang, Fan Tao, Haitao Zhang, Sujie Ma, Junxun Wang, Jinliang Liu, Zhefeng Cui, Pengfei Chen, Shixue Huang, Ziwei Wu, Zhaozhen Zhao, Lei Hu, Yi |
| description | Background
Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are reported to benefit from PD-1/PD-L1 inhibitors. However, additional biomarkers are needed, and whether tumor mutation burden (TMB) can be a robust biomarker or not is still controversial.
Objective
We conducted this study to assess TMB as a biomarker for PD-1/PD-L1 inhibitor treatment in advanced NSCLC patients in a real-world setting.
Patients and Methods
Chinese NSCLC patients who received a PD-1/PD-L1 inhibitor at the People’s Liberation Army General Hospital and who had pathological tissues available for TMB were retrospectively analyzed. Demographic and clinical information were evaluated. Targeted next-generation sequencing (NGS) of the tumor tissue was performed. The relationship between TMB and clinical benefit was assessed.
Results
Thirty-four patients treated with PD-1/PD-L1 inhibitors between March 2015 and January 2019 were analyzed. The TMB was greater in patients with complete response (CR)/partial response (PR) versus stable disease (SD) versus progressive disease (PD) (median 11 vs. 9.7 vs. 4.2 mutations/megabase [Mb];
p
= 0.049). The median progression-free survival was 10.6 months in the TMB-high group versus 3.9 months in the TMB-low group (cut-off value = 10 mutations/Mb) (hazard ratio [HR] 0.26 [95% confidence interval 0.12–0.57],
p
= 0.0007). The median overall survival was 21.0 months and 11.6 months (HR 0.37 [0.17–0.81],
p
= 0.0126) in the TMB-high group and the TMB-low group, respectively. The disease control rate was higher in the TMB-high group than in the TMB-low group (100% vs. 70%,
p
= 0.024).
Conclusions
High TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/PD-L1 inhibitors in China. Further studies are needed to confirm our findings. |
| doi_str_mv | 10.1007/s11523-020-00703-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2354737356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2356832899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-96c9050d4bd96384d36c554da0b18f2295cd57cc8f7dac4b5eae58d945dbceba3</originalsourceid><addsrcrecordid>eNp9kUtPAyEUhYnRaK3-AReGxI0bLI9hmFlqfTWp2kVN3BEGGB3tgMKMif9eaqsmLtxcIPc7h5t7ADgg-IRgLEaREE4ZwhSj9MQMsQ0wIELkiOb4YfP7zst8B-zG-IxxJijH22CHUZyUGR4AP-9bH-BN36mu8Q6e9cFYB1WECs58Z13XqAU8a3yrwosNsE7w7ByRUSpTAifuqamaL2Xj4Kl5V05bA2-9Q7FViwUc21SmvXuE42Ur7IGtWi2i3V-fQ3B_eTEfX6Pp3dVkfDpFmgneoTLXJebYZJUpc1ZkhuWa88woXJGiprTk2nChdVELo3RWcassL0yZcVNpWyk2BMcr39fg33obO9k2UadhlLO-j5IyngkmGM8TevQHffZ9cGm6JZUXjBZlmSi6onTwMQZby9fQpKV8SILlMg65ikOmOORXHJIl0eHauq9aa34k3_tPAFsBMbXcow2_f_9j-wmd3pPW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356832899</pqid></control><display><type>article</type><title>Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Huang, Di ; Zhang, Fan ; Tao, Haitao ; Zhang, Sujie ; Ma, Junxun ; Wang, Jinliang ; Liu, Zhefeng ; Cui, Pengfei ; Chen, Shixue ; Huang, Ziwei ; Wu, Zhaozhen ; Zhao, Lei ; Hu, Yi</creator><creatorcontrib>Huang, Di ; Zhang, Fan ; Tao, Haitao ; Zhang, Sujie ; Ma, Junxun ; Wang, Jinliang ; Liu, Zhefeng ; Cui, Pengfei ; Chen, Shixue ; Huang, Ziwei ; Wu, Zhaozhen ; Zhao, Lei ; Hu, Yi</creatorcontrib><description>Background
Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are reported to benefit from PD-1/PD-L1 inhibitors. However, additional biomarkers are needed, and whether tumor mutation burden (TMB) can be a robust biomarker or not is still controversial.
Objective
We conducted this study to assess TMB as a biomarker for PD-1/PD-L1 inhibitor treatment in advanced NSCLC patients in a real-world setting.
Patients and Methods
Chinese NSCLC patients who received a PD-1/PD-L1 inhibitor at the People’s Liberation Army General Hospital and who had pathological tissues available for TMB were retrospectively analyzed. Demographic and clinical information were evaluated. Targeted next-generation sequencing (NGS) of the tumor tissue was performed. The relationship between TMB and clinical benefit was assessed.
Results
Thirty-four patients treated with PD-1/PD-L1 inhibitors between March 2015 and January 2019 were analyzed. The TMB was greater in patients with complete response (CR)/partial response (PR) versus stable disease (SD) versus progressive disease (PD) (median 11 vs. 9.7 vs. 4.2 mutations/megabase [Mb];
p
= 0.049). The median progression-free survival was 10.6 months in the TMB-high group versus 3.9 months in the TMB-low group (cut-off value = 10 mutations/Mb) (hazard ratio [HR] 0.26 [95% confidence interval 0.12–0.57],
p
= 0.0007). The median overall survival was 21.0 months and 11.6 months (HR 0.37 [0.17–0.81],
p
= 0.0126) in the TMB-high group and the TMB-low group, respectively. The disease control rate was higher in the TMB-high group than in the TMB-low group (100% vs. 70%,
p
= 0.024).
Conclusions
High TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/PD-L1 inhibitors in China. Further studies are needed to confirm our findings.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-020-00703-3</identifier><identifier>PMID: 32052340</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Apoptosis ; Biomarkers ; Biomarkers, Tumor - metabolism ; Biomedicine ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Chemotherapy ; Deoxyribonucleic acid ; DNA ; FDA approval ; Female ; Hospitals ; Humans ; Immunotherapy - methods ; Ligands ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Original Research Article ; Patients ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Proteins</subject><ispartof>Targeted oncology, 2020-02, Vol.15 (1), p.93-100</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Targeted Oncology is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-96c9050d4bd96384d36c554da0b18f2295cd57cc8f7dac4b5eae58d945dbceba3</citedby><cites>FETCH-LOGICAL-c375t-96c9050d4bd96384d36c554da0b18f2295cd57cc8f7dac4b5eae58d945dbceba3</cites><orcidid>0000-0003-4740-0290</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11523-020-00703-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11523-020-00703-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32052340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Tao, Haitao</creatorcontrib><creatorcontrib>Zhang, Sujie</creatorcontrib><creatorcontrib>Ma, Junxun</creatorcontrib><creatorcontrib>Wang, Jinliang</creatorcontrib><creatorcontrib>Liu, Zhefeng</creatorcontrib><creatorcontrib>Cui, Pengfei</creatorcontrib><creatorcontrib>Chen, Shixue</creatorcontrib><creatorcontrib>Huang, Ziwei</creatorcontrib><creatorcontrib>Wu, Zhaozhen</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Hu, Yi</creatorcontrib><title>Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><addtitle>Target Oncol</addtitle><description>Background
Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are reported to benefit from PD-1/PD-L1 inhibitors. However, additional biomarkers are needed, and whether tumor mutation burden (TMB) can be a robust biomarker or not is still controversial.
Objective
We conducted this study to assess TMB as a biomarker for PD-1/PD-L1 inhibitor treatment in advanced NSCLC patients in a real-world setting.
Patients and Methods
Chinese NSCLC patients who received a PD-1/PD-L1 inhibitor at the People’s Liberation Army General Hospital and who had pathological tissues available for TMB were retrospectively analyzed. Demographic and clinical information were evaluated. Targeted next-generation sequencing (NGS) of the tumor tissue was performed. The relationship between TMB and clinical benefit was assessed.
Results
Thirty-four patients treated with PD-1/PD-L1 inhibitors between March 2015 and January 2019 were analyzed. The TMB was greater in patients with complete response (CR)/partial response (PR) versus stable disease (SD) versus progressive disease (PD) (median 11 vs. 9.7 vs. 4.2 mutations/megabase [Mb];
p
= 0.049). The median progression-free survival was 10.6 months in the TMB-high group versus 3.9 months in the TMB-low group (cut-off value = 10 mutations/Mb) (hazard ratio [HR] 0.26 [95% confidence interval 0.12–0.57],
p
= 0.0007). The median overall survival was 21.0 months and 11.6 months (HR 0.37 [0.17–0.81],
p
= 0.0126) in the TMB-high group and the TMB-low group, respectively. The disease control rate was higher in the TMB-high group than in the TMB-low group (100% vs. 70%,
p
= 0.024).
Conclusions
High TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/PD-L1 inhibitors in China. Further studies are needed to confirm our findings.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedicine</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chemotherapy</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>FDA approval</subject><subject>Female</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Original Research Article</subject><subject>Patients</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Proteins</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtPAyEUhYnRaK3-AReGxI0bLI9hmFlqfTWp2kVN3BEGGB3tgMKMif9eaqsmLtxcIPc7h5t7ADgg-IRgLEaREE4ZwhSj9MQMsQ0wIELkiOb4YfP7zst8B-zG-IxxJijH22CHUZyUGR4AP-9bH-BN36mu8Q6e9cFYB1WECs58Z13XqAU8a3yrwosNsE7w7ByRUSpTAifuqamaL2Xj4Kl5V05bA2-9Q7FViwUc21SmvXuE42Ur7IGtWi2i3V-fQ3B_eTEfX6Pp3dVkfDpFmgneoTLXJebYZJUpc1ZkhuWa88woXJGiprTk2nChdVELo3RWcassL0yZcVNpWyk2BMcr39fg33obO9k2UadhlLO-j5IyngkmGM8TevQHffZ9cGm6JZUXjBZlmSi6onTwMQZby9fQpKV8SILlMg65ikOmOORXHJIl0eHauq9aa34k3_tPAFsBMbXcow2_f_9j-wmd3pPW</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Huang, Di</creator><creator>Zhang, Fan</creator><creator>Tao, Haitao</creator><creator>Zhang, Sujie</creator><creator>Ma, Junxun</creator><creator>Wang, Jinliang</creator><creator>Liu, Zhefeng</creator><creator>Cui, Pengfei</creator><creator>Chen, Shixue</creator><creator>Huang, Ziwei</creator><creator>Wu, Zhaozhen</creator><creator>Zhao, Lei</creator><creator>Hu, Yi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4740-0290</orcidid></search><sort><creationdate>20200201</creationdate><title>Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer</title><author>Huang, Di ; Zhang, Fan ; Tao, Haitao ; Zhang, Sujie ; Ma, Junxun ; Wang, Jinliang ; Liu, Zhefeng ; Cui, Pengfei ; Chen, Shixue ; Huang, Ziwei ; Wu, Zhaozhen ; Zhao, Lei ; Hu, Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-96c9050d4bd96384d36c554da0b18f2295cd57cc8f7dac4b5eae58d945dbceba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedicine</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chemotherapy</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>FDA approval</topic><topic>Female</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Original Research Article</topic><topic>Patients</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Tao, Haitao</creatorcontrib><creatorcontrib>Zhang, Sujie</creatorcontrib><creatorcontrib>Ma, Junxun</creatorcontrib><creatorcontrib>Wang, Jinliang</creatorcontrib><creatorcontrib>Liu, Zhefeng</creatorcontrib><creatorcontrib>Cui, Pengfei</creatorcontrib><creatorcontrib>Chen, Shixue</creatorcontrib><creatorcontrib>Huang, Ziwei</creatorcontrib><creatorcontrib>Wu, Zhaozhen</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Hu, Yi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Di</au><au>Zhang, Fan</au><au>Tao, Haitao</au><au>Zhang, Sujie</au><au>Ma, Junxun</au><au>Wang, Jinliang</au><au>Liu, Zhefeng</au><au>Cui, Pengfei</au><au>Chen, Shixue</au><au>Huang, Ziwei</au><au>Wu, Zhaozhen</au><au>Zhao, Lei</au><au>Hu, Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><addtitle>Target Oncol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>15</volume><issue>1</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Background
Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are reported to benefit from PD-1/PD-L1 inhibitors. However, additional biomarkers are needed, and whether tumor mutation burden (TMB) can be a robust biomarker or not is still controversial.
Objective
We conducted this study to assess TMB as a biomarker for PD-1/PD-L1 inhibitor treatment in advanced NSCLC patients in a real-world setting.
Patients and Methods
Chinese NSCLC patients who received a PD-1/PD-L1 inhibitor at the People’s Liberation Army General Hospital and who had pathological tissues available for TMB were retrospectively analyzed. Demographic and clinical information were evaluated. Targeted next-generation sequencing (NGS) of the tumor tissue was performed. The relationship between TMB and clinical benefit was assessed.
Results
Thirty-four patients treated with PD-1/PD-L1 inhibitors between March 2015 and January 2019 were analyzed. The TMB was greater in patients with complete response (CR)/partial response (PR) versus stable disease (SD) versus progressive disease (PD) (median 11 vs. 9.7 vs. 4.2 mutations/megabase [Mb];
p
= 0.049). The median progression-free survival was 10.6 months in the TMB-high group versus 3.9 months in the TMB-low group (cut-off value = 10 mutations/Mb) (hazard ratio [HR] 0.26 [95% confidence interval 0.12–0.57],
p
= 0.0007). The median overall survival was 21.0 months and 11.6 months (HR 0.37 [0.17–0.81],
p
= 0.0126) in the TMB-high group and the TMB-low group, respectively. The disease control rate was higher in the TMB-high group than in the TMB-low group (100% vs. 70%,
p
= 0.024).
Conclusions
High TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/PD-L1 inhibitors in China. Further studies are needed to confirm our findings.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32052340</pmid><doi>10.1007/s11523-020-00703-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4740-0290</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1776-2596 |
| ispartof | Targeted oncology, 2020-02, Vol.15 (1), p.93-100 |
| issn | 1776-2596 1776-260X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2354737356 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Apoptosis Biomarkers Biomarkers, Tumor - metabolism Biomedicine Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Deoxyribonucleic acid DNA FDA approval Female Hospitals Humans Immunotherapy - methods Ligands Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Mutation Oncology Original Research Article Patients Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins |
| title | Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20Mutation%20Burden%20as%20a%20Potential%20Biomarker%20for%20PD-1/PD-L1%20Inhibition%20in%20Advanced%20Non-small%20Cell%20Lung%20Cancer&rft.jtitle=Targeted%20oncology&rft.au=Huang,%20Di&rft.date=2020-02-01&rft.volume=15&rft.issue=1&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-020-00703-3&rft_dat=%3Cproquest_cross%3E2356832899%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2356832899&rft_id=info:pmid/32052340&rfr_iscdi=true |